Quick Answer
Fulcrum Therapeutics, Inc. reported Diluted EPS of $1.18 per share (loss) for fiscal year 2025.
Fulcrum Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.18 | -637.5% |
| 2024 | -$0.16 | +89.9% |
| 2023 | -$1.59 | +34.8% |
| 2022 | -$2.44 | -6.6% |
| 2021 | -$2.29 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.31 | +11.4% | -10.7% |
| June 30, 2025 | -$0.28 | -132.2% | +0.0% |
| March 31, 2025 | -$0.28 | +34.9% | +20.0% |
| September 30, 2024 | -$0.35 | +10.3% | -140.2% |
| June 30, 2024 | $0.87 | +328.9% | +302.3% |
| March 31, 2024 | -$0.43 | -4.9% | -10.3% |
| September 30, 2023 | -$0.39 | +23.5% | -2.6% |
| June 30, 2023 | -$0.38 | +54.2% | +7.3% |
- Fulcrum Therapeutics, Inc. showed a decrease of -637.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Fulcrum Therapeutics, Inc.’s diluted eps has grown by 48.5% (from $2.29 per share (loss) to $1.18 per share (loss)).
- The most recent figure is from Fulcrum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: